Clinica Baviera (MC:CBAV) — Market Cap & Net Worth
Market Cap & Net Worth: Clinica Baviera (CBAV)
Clinica Baviera (MC:CBAV) has a market capitalization of $842.36 Million (€720.51 Million) as of September 24, 2026. Listed on the MC stock exchange, this Spain-based company holds position #9808 globally and #70 in its home market, demonstrating a 1.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clinica Baviera's stock price €57.20 by its total outstanding shares 16014366 (16.01 Million). Also see balance sheet size of Clinica Baviera for a full breakdown of the balance sheet.
Clinica Baviera Market Cap History: 2015 to 2026
Clinica Baviera's market capitalization history from 2015 to 2026. Data shows growth from $77.85 Million to $1.07 Billion (26.80% CAGR). Also see how efficiently does Clinica Baviera generate cash for how efficiently the company converts equity into cash flow.
Clinica Baviera Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clinica Baviera's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CBAV share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.22x
Clinica Baviera's market cap is 2.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.53x
Clinica Baviera's market cap is 14.53 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $77.85 Million | $85.53 Million | $4.84 Million | 0.91x | 16.09x |
| 2016 | $140.20 Million | $91.57 Million | $7.94 Million | 1.53x | 17.65x |
| 2017 | $129.73 Million | $99.88 Million | $9.88 Million | 1.30x | 13.14x |
| 2018 | $208.32 Million | $109.29 Million | $11.91 Million | 1.91x | 17.49x |
| 2019 | $227.14 Million | $124.33 Million | $12.90 Million | 1.83x | 17.61x |
| 2020 | $223.96 Million | $122.63 Million | $14.13 Million | 1.83x | 15.85x |
| 2021 | $354.26 Million | $172.73 Million | $27.93 Million | 2.05x | 12.68x |
| 2022 | $302.93 Million | $198.45 Million | $30.15 Million | 1.53x | 10.05x |
| 2023 | $413.45 Million | $224.92 Million | $36.75 Million | 1.84x | 11.25x |
| 2024 | $584.14 Million | $262.65 Million | $40.20 Million | 2.22x | 14.53x |
Competitor Companies of CBAV by Market Capitalization
Companies near Clinica Baviera in the global market cap rankings as of September 24, 2026. Review Clinica Baviera tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Clinica Baviera by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #155 globally with a market cap of $156.17 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #456 globally with a market cap of $60.75 Billion USD ( CN¥415.14 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #581 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.52 |
| #155 | Danaher Corporation | NYSE:DHR | $156.17 Billion | $221.09 |
| #456 | WuXi AppTec Co Ltd | SHG:603259 | $60.75 Billion | CN¥167.85 |
| #581 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $390.90 |
Clinica Baviera Historical Marketcap From 2015 to 2026
Between 2015 and today, Clinica Baviera's market cap moved from $77.85 Million to $ 1.07 Billion, with a yearly change of 26.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.07 Billion | +15.09% |
| 2025 | €930.51 Million | +59.29% |
| 2024 | €584.14 Million | +41.28% |
| 2023 | €413.45 Million | +36.48% |
| 2022 | €302.93 Million | -14.49% |
| 2021 | €354.26 Million | +58.18% |
| 2020 | €223.96 Million | -1.40% |
| 2019 | €227.14 Million | +9.03% |
| 2018 | €208.32 Million | +60.59% |
| 2017 | €129.73 Million | -7.47% |
| 2016 | €140.20 Million | +80.09% |
| 2015 | €77.85 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Clinica Baviera was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $842.36 Million USD |
| MoneyControl | $842.36 Million USD |
| MarketWatch | $842.36 Million USD |
| marketcap.company | $842.36 Million USD |
| Reuters | $842.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clinica Baviera
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmol… Read more